Advanced Biomed Inc. (NASDAQ:ADVB) Stock Short Interest Declines 48.4%

Advanced Biomed Inc. (NASDAQ:ADVB) was the recipient of a large drop in short interest in October. As of October 15th, there was short interest totaling 9,747 shares, a drop of 48.4% from the September 30th total of 18,897 shares. Based on an average trading volume of 16,412 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.8% of the shares of the stock are short sold.

Advanced Biomed Stock Down 12.9%

Shares of NASDAQ ADVB traded down $0.34 during trading on Friday, hitting $2.30. 21,780 shares of the company traded hands, compared to its average volume of 38,334. Advanced Biomed has a 1 year low of $2.25 and a 1 year high of $24.23. The company has a 50-day moving average price of $6.52 and a 200-day moving average price of $5.91. The firm has a market capitalization of $3.79 million, a P/E ratio of 0.48 and a beta of 0.01.

Advanced Biomed (NASDAQ:ADVB) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $0.44 earnings per share for the quarter.

Analyst Upgrades and Downgrades

ADVB has been the subject of several recent research reports. Weiss Ratings downgraded Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. Wall Street Zen downgraded shares of Advanced Biomed from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, Advanced Biomed currently has a consensus rating of “Sell”.

Advanced Biomed Company Profile

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.